Literature DB >> 2260490

Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer's disease.

T Ikeda1, Y Furukawa, S Mashimoto, K Takahashi, M Yamada.   

Abstract

Vitamin B12 levels in the serum and the cerebrospinal fluid (CSF) were compared between patients with Alzheimer's disease (AD) and senile dementia of Alzheimer's type (SDAT) (AD group) and patients with multi-infarct dementia (MID group). The B12 levels in the serum and the CSF were 742 +/- 359 pg/ml and 28 +/- 7 pg/ml (mean +/- SD), respectively, in the AD group, and 962 +/- 254 pg/ml and 50 +/- 26 pg/ml, respectively, in the MID group. CSF B12 levels were significantly lower in the AD group than in the MID group, whereas the serum levels were not different. At the same time, the serum levels of almost all patients were within the normal range, whereas the CSF levels were 25 pg/ml or lower in 10 of 12 AD patients. Therefore, this low level in the CSF is considered to be a characteristic finding in the AD group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2260490     DOI: 10.1111/j.1600-0447.1990.tb01395.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  8 in total

Review 1.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

Review 2.  Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia.

Authors:  Vincenzo Giordano; Gianfranco Peluso; Maurizio Iannuccelli; Paola Benatti; Raffaella Nicolai; Menotti Calvani
Journal:  Neurochem Res       Date:  2006-08-17       Impact factor: 3.996

3.  Influence of vitamin B12 on brain methionine adenosyltransferase activity in senile dementia of the Alzheimer's type.

Authors:  C Gomes-Trolin; C G Gottfries; B Regland; L Oreland
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.

Authors:  William A Banks
Journal:  Adv Drug Deliv Rev       Date:  2011-12-17       Impact factor: 15.470

5.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

6.  Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker.

Authors:  D Gunnersen; B Haley
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Amnionless (AMN) mutations in Imerslund-Gräsbeck syndrome may be associated with disturbed vitamin B12 transport into the CNS.

Authors:  A S Luder; S M Tanner; A de la Chapelle; J H Walter
Journal:  J Inherit Metab Dis       Date:  2008-01-07       Impact factor: 4.982

Review 8.  The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders.

Authors:  T Bottiglieri; K Hyland; E H Reynolds
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.